- Home
- TLRY vs DBVT Comparison
TLRY vs DBVT Comparison
Compare TLRY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | DBVT |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLRY | DBVT |
|---|---|---|
| Price | $9.08 | $24.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $103.33 | $31.75 |
| AVG Volume (30 Days) | ★ 6.1M | 452.2K |
| Earning Date | 01-08-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $837,323,000.00 | $5,502,000.00 |
| Revenue This Year | $7.57 | $1,768.71 |
| Revenue Next Year | $4.57 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $3.51 | $3.80 |
| 52 Week High | $23.20 | $26.19 |
Technical Indicators
Market Signals| Indicator | TLRY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 72.78 |
| Support Level | $8.61 | $16.69 |
| Resistance Level | $9.31 | $18.40 |
| Average True Range (ATR) | 0.56 | 1.45 |
| MACD | -0.26 | 0.57 |
| Stochastic Oscillator | 31.29 | 92.59 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.